Abstract
Although antiretroviral therapy has changed the clinical course of HIV infection, AIDS remains an incurable disease. Virus entry inhibitors, including maraviroc as the only registered representative of the class, represent a newly emerged group of anti-retrovirals with novel mechanism of action.
The primary endpoint is to evaluate the clinical efficacy parameter of maraviroc by measurig viral load at the end of the 4 week treatment period. The secondary endpoint is to evaluate the effectiveness of the drug by monitoring the changes of the viral load values and DC4+ cell counts during the period of 125 weeks.
Drug safety was also assessed. Data of 23 subjects were collected, 2 patients were from the Czech Republic and 21 patients from France.
Decrease in viral load in the 4th, 24th and 48th week was more than two orders of magnitude (-2.136; -2.448; -2.452 log10 copies/ml). The CD4+ cells led to an increase of values (71.71, 143.00, 196.43 cells/mm3).
Drug safety was assessed by monitoring the frequency of adverse effects. The data obtained were compared with the III. phase of clinical trials.
Our experience with maraviroc was positive. Maraviroc proved to be an effective antiretroviral agent for a combination therapy of HIV infection